Abstract
It has been hypothesized that didanosine has a low efficacy in the prevention and treatment of patients with the dementia complex of acquired immunodeficiency syndrome (AIDS) because "... the drug has not been detected in the cerebrospinal fluid". We investigated didanosine concentrations in cerebrospinal fluid (CSF) and plasma of four patients with AIDS who were using didanosine chronically. Didanosine levels, 4 h after the last drug administration, averaged 0.16 (+/- 0.03) mumol/l in CSF and 0.70 (+/- 0.27) mumol/l in plasma. When compared with historical data from patients using zidovudine, didanosine concentrations in CSF appeared to be approximately half (on a molar base) those of zidovudine concentrations in the CSF. Whether this difference in CSF levels is the explanation for the presumed lower efficacy of didanosine in the prevention and treatment of AIDS dementia complex remains to be proven. However, it is clear from this study, in contrast with earlier suggestions, that didanosine is able to pass the blood-CSF barrier in human immunodeficiency virus-infected individuals.
References
Dec 1, 1992·AIDS·R GeleziunasM A Wainberg
Oct 1, 1992·Antimicrobial Agents and Chemotherapy·M E MorganB D Anderson
Jan 17, 1991·The New England Journal of Medicine·K M ButlerH Moss
Apr 6, 1991·Lancet·F GrayR Gherardi
Jan 1, 1992·The Journal of Infectious Diseases·F M BalisP Jarosinski
Jul 1, 1991·Archives of Neurology·T A TartaglioneL Corey
May 1, 1991·Investigational New Drugs·M G WientjesJ E Tomaszewski
May 1, 1990·Clinical Pharmacology and Therapeutics·N R HartmanD G Johns
Jul 28, 1989·Science·R YarchoanS Broder
Sep 30, 1989·BMJ : British Medical Journal·P PortegiesJ Goudsmit
Jan 17, 1987·Lancet·R YarchoanA Brunetti
Dec 15, 1988·The New England Journal of Medicine·F A SchmittJ L Drucker
Oct 6, 1988·The New England Journal of Medicine·P A PizzoM Rubin
Sep 10, 1994·Lancet·P PortegiesJ M Lange
Feb 1, 1994·Pharmaceutical Research·T TuntlandJ D Unadkat
Dec 1, 1993·AIDS·D M BurgerJ H Beijnen
May 1, 1993·AIDS·P PortegiesJ Goudsmit
May 1, 1993·AIDS·V TozziM P Camporiondo
Feb 1, 1993·Clinical Pharmacokinetics·G D MorseA M O'Donnell
Apr 1, 1993·Annals of Neurology·J J SidtisK Kieburtz
Citations
Jan 16, 2008·Archives of Neurology·Scott LetendreUNKNOWN CHARTER Group
Jun 6, 2000·Advanced Drug Delivery Reviews·R J Sawchuk, Z Yang
Dec 14, 2011·The Journal of Antimicrobial Chemotherapy·Aylin YilmazMagnus Gisslén
Jan 6, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Brookie M BestUNKNOWN CHARTER Study Group
Dec 31, 1997·The Journal of Clinical Investigation·A B van't WoutH Schuitemaker
Oct 26, 2016·AIDS Research and Treatment·Jacinta Nwamaka NwoguBabafemi Taiwo
Aug 29, 2003·Journal of the International Association of Physicians in AIDS Care : JIAPAC·David A Cooper
Dec 12, 2001·HIV Medicine·M Gisslén, L Hagberg
Nov 14, 1998·AIDS·R H EntingP Portegies
Aug 3, 2002·CNS Drugs·Heather E WynnCourtney V Fletcher
Sep 10, 2014·Clinical Pharmacokinetics·Andrea CalcagnoStefano Bonora
Aug 24, 1999·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S KravcikD W Cameron
Aug 14, 2019·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Sipho MdandaThavendran Govender
Feb 4, 2003·Journal of Neurochemistry·J E GibbsS A Thomas
Apr 27, 2013·Molecular Pharmaceutics·Catia MarzoliniAnna Seelig